Is IKT or SANA more profitable?

Inhibikase Therapeutics' return on equity of -41.31% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -41.31% -38.98% Sana Biotechnology N/A -108.01% -40.68%

Does the media prefer IKT or SANA?

In the previous week, Inhibikase Therapeutics had 9 more articles in the media than Sana Biotechnology. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 3 mentions for Sana Biotechnology. Inhibikase Therapeutics' average media sentiment score of 0.85 beat Sana Biotechnology's score of 0.47 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IKT or PHAR?

In the previous week, Inhibikase Therapeutics had 5 more articles in the media than Pharming Group. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 7 mentions for Pharming Group. Inhibikase Therapeutics' average media sentiment score of 0.85 beat Pharming Group's score of 0.27 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IKT or KURA?

In the previous week, Inhibikase Therapeutics had 5 more articles in the media than Kura Oncology. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 7 mentions for Kura Oncology. Inhibikase Therapeutics' average media sentiment score of 0.85 beat Kura Oncology's score of -0.62 indicating that Inhibikase Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media favor SPRY or IKT?

In the previous week, Inhibikase Therapeutics had 10 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.93 beat Inhibikase Therapeutics' score of 0.85 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibikase Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Inhibikase Therapeutics (IKT) Competitors

$1.67 -0.03 (-1.76%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$1.68 +0.01 (+0.30%)

As of 06/3/2026 04:55 PM Eastern

Compare

IKT vs. SANA, PHAR, KURA, ABUS, and SPRY

Should you buy Inhibikase Therapeutics stock or one of its competitors? MarketBeat compares Inhibikase Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Inhibikase Therapeutics include Sana Biotechnology (SANA), Pharming Group (PHAR), Kura Oncology (KURA), Arbutus Biopharma (ABUS), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry.

How does Inhibikase Therapeutics compare to Sana Biotechnology?

Inhibikase Therapeutics (NASDAQ:IKT) and Sana Biotechnology (NASDAQ:SANA) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Inhibikase Therapeutics had 9 more articles in the media than Sana Biotechnology. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 3 mentions for Sana Biotechnology. Inhibikase Therapeutics' average media sentiment score of 0.85 beat Sana Biotechnology's score of 0.47 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Inhibikase Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Inhibikase Therapeutics' return on equity of -41.31% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Sana Biotechnology	N/A	-108.01%	-40.68%

Inhibikase Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 229.34%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 204.49%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Inhibikase Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 25.4% of Sana Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Inhibikase Therapeutics has higher revenue and earnings than Sana Biotechnology. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	848.04	-$48.26M	-$0.43	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

Summary

Inhibikase Therapeutics beats Sana Biotechnology on 10 of the 15 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Pharming Group?

Inhibikase Therapeutics (NASDAQ:IKT) and Pharming Group (NASDAQ:PHAR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

In the previous week, Inhibikase Therapeutics had 5 more articles in the media than Pharming Group. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 7 mentions for Pharming Group. Inhibikase Therapeutics' average media sentiment score of 0.85 beat Pharming Group's score of 0.27 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Pharming Group shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pharming Group has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	848.04	-$48.26M	-$0.43	N/A
Pharming Group	$376.13M	2.30	$2.85M	$0.16	76.50

Pharming Group has a net margin of 3.30% compared to Inhibikase Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Pharming Group	3.30%	4.64%	2.55%

Inhibikase Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

Inhibikase Therapeutics presently has a consensus price target of $5.50, indicating a potential upside of 229.34%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 213.18%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than Pharming Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Inhibikase Therapeutics beats Pharming Group on 9 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Kura Oncology?

Inhibikase Therapeutics (NASDAQ:IKT) and Kura Oncology (NASDAQ:KURA) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, dividends, valuation, profitability, media sentiment and analyst recommendations.

3.8% of Inhibikase Therapeutics shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 7.6% of Kura Oncology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inhibikase Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 229.34%. Kura Oncology has a consensus price target of $25.90, suggesting a potential upside of 199.25%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Inhibikase Therapeutics is more favorable than Kura Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13
Kura Oncology	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

Inhibikase Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the broader market. Comparatively, Kura Oncology has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

In the previous week, Inhibikase Therapeutics had 5 more articles in the media than Kura Oncology. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 7 mentions for Kura Oncology. Inhibikase Therapeutics' average media sentiment score of 0.85 beat Kura Oncology's score of -0.62 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Kura Oncology	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

Inhibikase Therapeutics has higher earnings, but lower revenue than Kura Oncology. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	848.04	-$48.26M	-$0.43	N/A
Kura Oncology	$67.48M	11.39	-$278.67M	-$3.35	N/A

Inhibikase Therapeutics has a net margin of 0.00% compared to Kura Oncology's net margin of -411.19%. Inhibikase Therapeutics' return on equity of -41.31% beat Kura Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-41.31%	-38.98%
Kura Oncology	-411.19%	-141.95%	-43.28%

Summary

Inhibikase Therapeutics beats Kura Oncology on 13 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

In the previous week, Inhibikase Therapeutics had 11 more articles in the media than Arbutus Biopharma. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 1 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.28 beat Inhibikase Therapeutics' score of 0.85 indicating that Arbutus Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Arbutus Biopharma	Positive
Inhibikase Therapeutics	Positive

Arbutus Biopharma has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.92, suggesting that its stock price is 8% less volatile than the broader market.

Arbutus Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 14.94%. Inhibikase Therapeutics has a consensus price target of $5.50, indicating a potential upside of 229.34%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13

Arbutus Biopharma has higher revenue and earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	61.03	-$33.50M	$0.83	5.24
Inhibikase Therapeutics	$260K	848.04	-$48.26M	-$0.43	N/A

Arbutus Biopharma has a net margin of 83.95% compared to Inhibikase Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Inhibikase Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

43.8% of Arbutus Biopharma shares are owned by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Arbutus Biopharma beats Inhibikase Therapeutics on 10 of the 17 factors compared between the two stocks.

How does Inhibikase Therapeutics compare to ARS Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Inhibikase Therapeutics (NASDAQ:IKT) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, institutional ownership, earnings, analyst recommendations, dividends, profitability and media sentiment.

ARS Pharmaceuticals has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market. Comparatively, Inhibikase Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

Inhibikase Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Inhibikase Therapeutics' return on equity of -41.31% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Inhibikase Therapeutics	N/A	-41.31%	-38.98%

Inhibikase Therapeutics has lower revenue, but higher earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Inhibikase Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	10.31	-$171.30M	-$2.01	N/A
Inhibikase Therapeutics	$260K	848.04	-$48.26M	-$0.43	N/A

In the previous week, Inhibikase Therapeutics had 10 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 12 mentions for Inhibikase Therapeutics and 2 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.93 beat Inhibikase Therapeutics' score of 0.85 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibikase Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

ARS Pharmaceuticals currently has a consensus target price of $28.60, indicating a potential upside of 226.86%. Inhibikase Therapeutics has a consensus target price of $5.50, indicating a potential upside of 229.34%. Given Inhibikase Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Inhibikase Therapeutics is more favorable than ARS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	4 Strong Buy rating(s)	3.13

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 3.8% of Inhibikase Therapeutics shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of Inhibikase Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Inhibikase Therapeutics beats ARS Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

Get Inhibikase Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IKT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IKT vs. The Competition

Export

Metric	Inhibikase Therapeutics	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$224.46M	$432.88M	$4.30B	$12.54B
Dividend Yield	N/A	N/A	7.42%	5.22%
P/E Ratio	-3.88	N/A	21.69	24.18
Price / Sales	848.04	325.30	177.05	112.26
Price / Cash	N/A	N/A	58.60	57.13
Price / Book	0.73	2.62	32.78	6.72
Net Income	-$48.26M	-$81.71M	$109.80M	$337.19M
7 Day Performance	-5.65%	-6.74%	-0.94%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	N/A	N/A	15.31%	33.10%

Inhibikase Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IKT Inhibikase Therapeutics	2.3867 of 5 stars	$1.67 -1.8%	$5.50 +229.3%	N/A	$224.46M	$260K	N/A	6	News Coverage
SANA Sana Biotechnology	3.4482 of 5 stars	$3.21 -2.7%	$9.50 +196.0%	+33.3%	$918.36M	N/A	N/A	380
PHAR Pharming Group	3.7743 of 5 stars	$13.10 +0.8%	$38.33 +192.6%	+5.4%	$917.42M	$376.13M	81.88	280
KURA Kura Oncology	2.1771 of 5 stars	$9.03 -11.5%	$25.90 +186.8%	+34.8%	$905.50M	$67.48M	N/A	130
ABUS Arbutus Biopharma	2.2221 of 5 stars	$4.48 -1.8%	$5.00 +11.6%	+26.1%	$900.77M	$14.08M	5.40	90	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IKT) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inhibikase Therapeutics (IKT) Competitors

IKT vs. SANA, PHAR, KURA, ABUS, and SPRY

How does Inhibikase Therapeutics compare to Sana Biotechnology?

Summary

How does Inhibikase Therapeutics compare to Pharming Group?

Summary

How does Inhibikase Therapeutics compare to Kura Oncology?

Summary

How does Inhibikase Therapeutics compare to Arbutus Biopharma?

Summary

How does Inhibikase Therapeutics compare to ARS Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inhibikase Therapeutics (IKT) Competitors

IKT vs. SANA, PHAR, KURA, ABUS, and SPRY

How does Inhibikase Therapeutics compare to Sana Biotechnology?

Does the media prefer IKT or SANA?

Which has more risk and volatility, IKT or SANA?

Is IKT or SANA more profitable?

Do analysts rate IKT or SANA?

Do insiders and institutionals believe in IKT or SANA?

Which has better earnings and valuation, IKT or SANA?

Summary

How does Inhibikase Therapeutics compare to Pharming Group?

Does the media prefer IKT or PHAR?

Do institutionals and insiders believe in IKT or PHAR?

Which has preferable valuation & earnings, IKT or PHAR?

Is IKT or PHAR more profitable?

Which has more volatility & risk, IKT or PHAR?

Do analysts recommend IKT or PHAR?

Summary

How does Inhibikase Therapeutics compare to Kura Oncology?

Do insiders & institutionals have more ownership in IKT or KURA?

Do analysts prefer IKT or KURA?

Which has more volatility & risk, IKT or KURA?

Does the media prefer IKT or KURA?

Which has stronger earnings and valuation, IKT or KURA?

Is IKT or KURA more profitable?

Summary

How does Inhibikase Therapeutics compare to Arbutus Biopharma?

Does the media refer more to ABUS or IKT?

Which has more volatility and risk, ABUS or IKT?

Do analysts rate ABUS or IKT?

Which has stronger earnings and valuation, ABUS or IKT?

Is ABUS or IKT more profitable?

Do insiders and institutionals have more ownership in ABUS or IKT?

Summary

How does Inhibikase Therapeutics compare to ARS Pharmaceuticals?

Which has more volatility and risk, SPRY or IKT?

Is SPRY or IKT more profitable?

Which has stronger valuation & earnings, SPRY or IKT?

Does the media favor SPRY or IKT?

Do analysts recommend SPRY or IKT?

Do institutionals & insiders believe in SPRY or IKT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IKT vs. The Competition

Inhibikase Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools